Equities analysts expect Bicycle Therapeutics plc (NASDAQ:BCYC – Get Rating) to report $3.70 million in sales for the current quarter, according to Zacks. Eight analysts have issued estimates for Bicycle Therapeutics’ earnings. The lowest sales estimate is $2.00 million and the highest is $4.18 million. Bicycle Therapeutics reported sales of $1.79 million during the same quarter last year, which would suggest a positive year over year growth rate of 106.7%. The company is expected to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Bicycle Therapeutics will report full-year sales of $15.83 million for the current year, with estimates ranging from $14.00 million to $17.55 million. For the next fiscal year, analysts forecast that the business will report sales of $18.34 million, with estimates ranging from $14.70 million to $25.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Bicycle Therapeutics.
Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.25). Bicycle Therapeutics had a negative net margin of 568.71% and a negative return on equity of 31.61%.
Shares of BCYC opened at $17.02 on Friday. The company has a market capitalization of $504.57 million, a PE ratio of -5.89 and a beta of 0.55. Bicycle Therapeutics has a 12 month low of $16.08 and a 12 month high of $62.08. The stock’s 50-day moving average price is $30.62 and its two-hundred day moving average price is $44.57. The company has a current ratio of 12.14, a quick ratio of 12.14 and a debt-to-equity ratio of 0.09.
Large investors have recently bought and sold shares of the stock. Citigroup Inc. raised its holdings in shares of Bicycle Therapeutics by 424.2% during the fourth quarter. Citigroup Inc. now owns 802 shares of the company’s stock worth $49,000 after purchasing an additional 649 shares during the last quarter. Prospera Financial Services Inc acquired a new stake in shares of Bicycle Therapeutics in the first quarter valued at about $88,000. Bank of America Corp DE grew its position in shares of Bicycle Therapeutics by 17.1% in the fourth quarter. Bank of America Corp DE now owns 2,524 shares of the company’s stock valued at $153,000 after purchasing an additional 368 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Bicycle Therapeutics by 107.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,828 shares of the company’s stock worth $172,000 after buying an additional 1,463 shares in the last quarter. Finally, Northern Trust Corp purchased a new position in shares of Bicycle Therapeutics in the fourth quarter worth about $177,000. 71.99% of the stock is owned by institutional investors.
Bicycle Therapeutics Company Profile (Get Rating)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
- Get a free copy of the StockNews.com research report on Bicycle Therapeutics (BCYC)
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- A Reversal In The S&P 500 Is Confirmed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.